These results indicated that the clinical significance of PD-1/PD-L1/CTLA-4 and clinical response of PD-1/PD-L1/CTLA-4 inhibitors are limited in ovarian cancer. This evidence concerns the gene CTLA4 and ovarian carcinoma.